ALK and neuroblastoma: In July 2016, the clinical trial called Next Generation Personalized Neuroblastoma Therapy (NEPENTHE) was initiated: it had been enrolling patients between 1-21 years old with a refractory or relapsed neuroblastoma with alterations of the ALK gene [146,147,148,149,150].